BBNX
Beta Bionics, Inc.NASDAQHealthcare$9.93-0.80%ClosedMarket Cap: $440.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.40
P/S
4.41
EV/EBITDA
-6.60
DCF Value
$-79.23
FCF Yield
-10.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
55.4%
Operating Margin
-71.5%
Net Margin
-73.0%
ROE
-24.4%
ROA
-22.3%
ROIC
-23.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $32.1M | 59.0% | $-16.1M | $-13.5M | $-0.30 | — |
| FY 2025 | $100.3M | 55.4% | $-71.7M | $-73.2M | $-1.81 | — |
| Q3 2025 | $27.3M | 55.5% | $-17.0M | $-14.2M | $-0.33 | — |
| Q2 2025 | $23.2M | 53.8% | $-19.9M | $-16.9M | $-0.39 | — |
| Q1 2025 | $17.6M | 50.9% | $-18.6M | $-28.7M | $-0.93 | — |
| Q4 2024 | $20.4M | 57.2% | $-13.0M | $-18.1M | $-0.42 | — |
| FY 2024 | $65.1M | 55.1% | $-45.3M | $-54.8M | $-8.60 | — |
| Q3 2024 | $16.7M | 53.4% | $-11.0M | $-9.7M | $-1.55 | — |
| Q2 2024 | $15.0M | 53.7% | $-11.8M | $-14.5M | $-0.33 | — |
| Q1 2024 | $12.9M | 55.7% | $-9.5M | $-12.4M | $-0.41 | — |
| Q4 2023 | $8.3M | 60.6% | $-8.4M | $-18.8M | $-3.13 | — |
| FY 2023 | $12.0M | 52.6% | $-35.9M | $-44.1M | $-8.31 | — |